Insights into non-classic and emerging causes of hypopituitarism
Hypopituitarism is defined as one or more partial or complete pituitary hormone deficiencies,
which are related to the anterior and/or posterior gland and can have an onset in childhood …
which are related to the anterior and/or posterior gland and can have an onset in childhood …
Living with metastatic cancer: a roadmap for future research
Simple Summary Although people with metastatic cancer are living longer with their
disease, they are faced with challenges that can interfere with their quality of life. These …
disease, they are faced with challenges that can interfere with their quality of life. These …
Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
SJ Bagley, S Kothari, C Aggarwal, JM Bauml, EW Alley… - Lung cancer, 2017 - Elsevier
Objectives Efficient use of nivolumab in non-small-cell lung cancer (NSCLC) has been
limited by the lack of a definitive predictive biomarker. In patients with metastatic melanoma …
limited by the lack of a definitive predictive biomarker. In patients with metastatic melanoma …
Adverse effects of immune checkpoint therapy in cancer patients visiting the emergency department of a comprehensive cancer center
Study objective Cancer immunotherapy is evolving rapidly and is transforming cancer care.
During the last decade, immune checkpoint therapies have been developed to enhance the …
During the last decade, immune checkpoint therapies have been developed to enhance the …
Biomarkers for response of melanoma patients to immune checkpoint inhibitors: a systematic review
Background Immune checkpoint inhibitors (ICIs), targeting CTLA-4 or PD-1 molecules, have
shown impressive therapeutic results. However, only 20–40% of advanced melanoma …
shown impressive therapeutic results. However, only 20–40% of advanced melanoma …
TNFR2: Role in cancer immunology and immunotherapy
Immune checkpoint inhibitors (ICIs), including anti-CTLA-4 (cytotoxic T lymphocyte antigen-
4) and anti-PD-1/PD-L1 (programmed death-1/programmed death-ligand 1), represent a …
4) and anti-PD-1/PD-L1 (programmed death-1/programmed death-ligand 1), represent a …
Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities
Immune checkpoint inhibitors (ICIs) have transformed the treatment of patients with
advanced cancers. However, the majority of patients do not respond or develop early …
advanced cancers. However, the majority of patients do not respond or develop early …
Vogt-Koyanagi-Harada–like syndrome complicating pembrolizumab treatment for metastatic melanoma
M Bricout, A Petre, M Amini-Adle, W Bezza… - Journal of …, 2017 - journals.lww.com
Abstract Vogt-Koyanagi-Harada (VKH) syndrome is a rare condition implicating systemic
immune reaction against melanocytes. The pathophysiology is unclear. A genetic …
immune reaction against melanocytes. The pathophysiology is unclear. A genetic …
New causes of hypophysitis
KCJ Yuen, V Popovic, PJ Trainer - Best Practice & Research Clinical …, 2019 - Elsevier
Hypophysitis is a rare entity characterized by inflammation of the pituitary gland and its stalk
that can cause hypopituitarism and/or mass effect. Etiology can be categorized as primary or …
that can cause hypopituitarism and/or mass effect. Etiology can be categorized as primary or …
Immune checkpoint blockade: the new frontier in cancer treatment
JM Clarke, DJ George, S Lisi, AKS Salama - Targeted oncology, 2018 - Springer
Immune checkpoint blockers have revolutionized cancer treatment in recent years. These
agents are now approved for the treatment of several malignancies, including melanoma …
agents are now approved for the treatment of several malignancies, including melanoma …